logo
logo

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

Feb 14, 2024•over 1 year ago

Amount Raised

$123 Million

Round Type

series b

CambridgeBiotechnology

Investors

Wtt Investment LtdArkin Bio CapitalGordon Freeman, Ph DBinney Street CapitalSixty Degree CapitalInvusSanofi VenturesLeaps By BayerMpm Bio ImpactCatalio Capital Management

Description

NextPoint Therapeutics announced the closing of a $42.5M Extension to its Series B financing round, resulting in a total of $122.5M raised. The funds will be used to advance the company’s immuno-oncology clinical programs and propel the development of additional therapeutic modalities targeting the novel HHLA2 tumor antigen.

Company Information

Company

NextPoint Therapeutics

Location

238 MAIN STREET

Cambridge, Maryland, United States

About

Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People